Stock Research Monitor: SURF, SYN, and TLGT
LONDON, UK / ACCESSWIRE / May 21, 2018 / If you want a free Stock Review on TSRO sign up now at www.wallstequities.com/registration. On Friday, the NASDAQ Composite ended the day at 7,354.34, down 0.38%; the Dow Jones Industrial Average ended flat, to finish at 24,715.09; and the S&P 500 closed at 2,712.97, marginally slipping 0.26%. US markets saw six out of nine sectors finishing the day in red and three in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Surface Oncology Inc. (SURF), Synthetic Biologics Inc. (NYSE AMER: SYN), Teligent Inc. (NASDAQ: TLGT), Tesaro Inc. (NASDAQ: TSRO). All you have to do is sign up today for this free limited time offer by clicking the link below.
Cambridge, Massachusetts headquartered Surface Oncology Inc.'s stock finished Friday's session 2.14% higher at $14.29 with a total trading volume of 219,782 shares. The stock has gained 7.20% in the past month. Shares of the Company, which engages in the development of cancer therapies, are trading above their 50-day and 200-day moving averages by 2.38% and 2.38%, respectively.
On May 14th, 2018, research firm Goldman initiated a 'Neutral' rating on the Company's stock, with a target price of $17 per share. Get the full research report on SURF for free by clicking below at:
Shares in Rockville, Maryland headquartered Synthetic Biologics Inc. rose 1.05%, ending last Friday's session at $0.25 with a total trading volume of 520,369 shares. The Company's shares are trading below their 50-day moving average by 19.93%. Moreover, shares of Synthetic Biologics, which develops therapeutics designed to preserve the microbiome to protect and restore the health of patients, have an RSI of 39.98. Gain free access to the research report on SYN at:
On Friday, Buena, New Jersey-based Teligent Inc.'s stock saw a rise of 0.70%, to close the day at $2.87. A total volume of 285,859 shares was traded. The stock is trading below its 50-day moving average by 6.31%. Additionally, shares of Teligent, which develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the US and Canada, have an RSI of 42.43. Register for your free report coverage on TLGT at:
Shares in Waltham, Massachusetts headquartered Tesaro Inc. ended the day 5.67% lower at $47.71. A total volume of 1.62 million shares was traded, which was above their three months average volume of 1.10 million shares. The Company's shares are trading below their 50-day moving average by 13.37%. Furthermore, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US, have an RSI of 41.15.
On May 07th, 2018, research firm Lake Street reiterated its ‘Buy' rating on the Company's stock with a decrease of the target price from $120 a share to $80 a share. Get the free research report on TSRO at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities